Planex Plus20 gm

Planex Plus 20 gm is a fixed-dose topical combination indicated for the treatment of plaque psoriasis (psoriasis vulgaris) of the skin and scalp in patients whose disease is suitable for topical therapy.

• Established/approved use: Once-daily topical treatment of plaque psoriasis in adults (ointment, gel, and foam formulations); certain formulations are approved for adolescents 12 years and above.
• Guideline-supported use: Recommended by dermatology treatment guidelines as a first-line topical option for mild-to-moderate plaque psoriasis, and it is generally preferred over either monotherapy component alone because it achieves faster and more complete clearance.
• Scalp psoriasis: Gel and foam formulations of Planex Plus 20 gm are specifically used for plaque psoriasis of the scalp.
• Long-term/maintenance use: Some formulations are approved for intermittent use for up to 52 weeks under physician supervision, with periodic reassessment.

Planex Plus 20 gm is not indicated for erythrodermic, exfoliative, or guttate psoriasis, and is not intended for use on the face, groin, axillae, or other skin-fold areas.

Planex Plus 20 gm combines two active ingredients that act on different pathways of psoriatic disease:

• Betamethasone (as dipropionate) - a potent synthetic corticosteroid, typically 0.05% w/w.
• Calcipotriol (calcipotriene) - a synthetic vitamin D3 analogue, typically 0.005% w/w.

It is formulated as an ointment, topical suspension/gel, or cutaneous foam, depending on the brand and intended site of application (body, scalp).

Planex Plus 20 gm is a topical, fixed-dose combination product used in dermatology for plaque psoriasis. It brings together a corticosteroid and a vitamin D3 analogue in a single application, which improves patient adherence compared with using two separate products.

The corticosteroid component provides rapid anti-inflammatory, antipruritic, and vasoconstrictive effects, while the vitamin D3 analogue component normalizes the excessive skin cell growth (keratinocyte proliferation) and abnormal differentiation seen in psoriatic plaques. Combining the two also allows calcipotriol to counteract some skin-thinning effects of the corticosteroid, and the corticosteroid reduces skin irritation that calcipotriol can cause when used alone.

Planex Plus 20 gm is available in Bangladesh as an ointment and as a topical suspension under various brand names.

Planex Plus 20 gm belongs to the therapeutic class of topical antipsoriatic combination agents, combining a Group I-II (potent) topical corticosteroid with a topical vitamin D3 analogue. It is classified under dermatological preparations used for the local treatment of psoriasis.

Planex Plus 20 gm exerts its therapeutic effect through two complementary mechanisms:

• Betamethasone dipropionate: A potent glucocorticoid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory proteins (e.g., lipocortins) that inhibit phospholipase A2, thereby reducing synthesis of inflammatory mediators (prostaglandins, leukotrienes). This produces anti-inflammatory, antipruritic, and vasoconstrictive effects, decreasing the redness, scaling, and itching of psoriatic plaques.
• Calcipotriol: A synthetic analogue of calcitriol (active vitamin D3) that binds the vitamin D receptor in keratinocytes, regulating gene transcription to inhibit excessive keratinocyte proliferation and promote normal differentiation, which reduces the plaque thickening and scaling characteristic of psoriasis.

Systemic absorption of both components through intact skin is generally low but can increase with application to large body surface areas, use of occlusive dressings, or use on damaged/inflamed skin, increasing the risk of systemic corticosteroid and vitamin D effects.

Planex Plus 20 gm is for topical (external) use only - it must never be taken by mouth, applied to the eyes, mucous membranes, or open wounds. Apply a thin layer to clean, dry skin over the psoriatic plaques once daily, gently rubbing it in until absorbed. Wash hands after application unless the hands are part of the treated area. Do not bandage or cover the treated area (occlude) unless a physician has specifically advised it, as this increases drug absorption and side-effect risk.

Clinically significant interactions with Planex Plus 20 gm are limited because systemic absorption from topical use is generally low, but the following should be noted:

• Other vitamin D analogues or calcium supplements: Concurrent use with other vitamin D-containing products or high-dose calcium supplementation may increase the risk of hypercalcemia; avoid combining without medical guidance.
• Other topical or systemic corticosteroids: Concomitant use of additional corticosteroid-containing products increases the cumulative corticosteroid load and the risk of HPA-axis suppression and skin atrophy.
• Other topical psoriasis treatments (e.g., salicylic acid, coal tar, phototherapy): Concurrent use of certain keratolytic agents may reduce calcipotriol's stability/efficacy or increase irritation; medical advice should be sought before combining products.

Always inform the physician or pharmacist about all other topical and systemic medicines, including over-the-counter products, being used.

Most adverse effects of Planex Plus 20 gm are local and mild-to-moderate:

• Common: Pruritus (itching), skin irritation, burning sensation at the application site, erythema (redness).
• Less common: Folliculitis, skin dryness, exacerbation of psoriasis, rash, pain or other skin discomfort.
• Uncommon but important (usually with prolonged/extensive use): Skin atrophy, telangiectasia, striae, hypopigmentation, hypercalcemia, and (very rarely) systemic corticosteroid effects (see Precautions and Warnings).

Patients should report any unusual or persistent skin reaction, or symptoms suggestive of hypercalcemia (e.g., nausea, weakness, excessive thirst), to their physician.

Pregnancy: Data on the use of Planex Plus 20 gm in pregnant women are limited. Animal studies with the individual components have shown potential for fetal effects at high systemic exposure. Planex Plus 20 gm should be used during pregnancy only if clearly needed, at the lowest effective dose and for the shortest duration, and only after consulting a physician who has weighed the potential benefit against the potential risk to the fetus.

Lactation: It is not known whether topically applied betamethasone or calcipotriol are excreted in breast milk in clinically significant amounts. As a precaution, Planex Plus 20 gm should not be applied directly to the breast/nipple area before breastfeeding, and use elsewhere on the body should be limited to the smallest area and shortest duration necessary, under medical advice.

The following precautions apply when using Planex Plus 20 gm:

• Maximum dose/duration: Do not exceed the recommended maximum weekly quantity or treatment duration, as excessive use increases the risk of hypercalcemia and HPA-axis suppression.
• Site restrictions: Avoid application to the face, scalp hairline, groin, axillae, and other skin folds, where absorption is higher and skin is more sensitive to corticosteroid side effects.
• Calcium metabolism: Monitor for signs of hypercalcemia, especially with extensive body surface area treatment or prolonged use; discontinue if hypercalcemia occurs and reassess.
• Skin infections: Do not use on skin with untreated bacterial, fungal, or viral infections, as corticosteroids can mask or worsen these infections.
• Withdrawal: Abrupt discontinuation of potent topical corticosteroids after prolonged use may cause rebound flare of psoriasis; taper under medical guidance if long-term use is stopped.
• Ocular exposure: Avoid contact with the eyes; prolonged periocular corticosteroid exposure can increase risk of cataracts and glaucoma.
• Occlusion: Avoid occlusive dressings unless specifically directed, as this substantially increases systemic absorption.

Topical overuse or ingestion of Planex Plus 20 gm is unlikely to cause acute life-threatening toxicity, but excessive or prolonged application over large body areas can lead to systemic corticosteroid effects (e.g., Cushingoid features, HPA-axis suppression) and hypercalcemia (nausea, vomiting, constipation, weakness, confusion). If accidental ingestion occurs, or if signs of hypercalcemia or systemic corticosteroid excess develop, seek immediate medical attention or contact a poison control center. Do not attempt to manage overdose at home without professional guidance.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the container tightly closed and out of reach of children.

Pediatric use: Certain formulations of Planex Plus 20 gm are approved for adolescents 12 years and older at a reduced maximum weekly quantity; safety and efficacy in children under 12 years have not been established, and use in this age group is generally not recommended.

Elderly: No specific dose adjustment is generally required in elderly patients, but skin in older adults may be thinner and more prone to corticosteroid-related atrophy, so monitoring is advised.

Renal/hepatic impairment: No formal dose adjustment guidelines are established for topical use, but caution is advised in patients with severe renal or hepatic impairment, as they may be more susceptible to systemic effects if significant absorption occurs; use the smallest effective area and duration.

Standard treatment courses of Planex Plus 20 gm are limited to 4 weeks of continuous once-daily use for an acute psoriatic flare. For long-term disease control, intermittent use (e.g., only as needed for flares, or on selected days per week) for up to 52 weeks may be prescribed under physician supervision, with regular reassessment of skin condition and calcium status. Treatment should not be continued beyond the period advised by the physician without follow-up review.

Topical corticosteroid + vitamin D3 analogue combination (antipsoriatic agent)

Planex Plus 20 gm works through two complementary actions: betamethasone (a potent corticosteroid) suppresses local inflammation, reduces immune cell activity, and constricts blood vessels in the skin, relieving redness and itching; calcipotriol (a vitamin D3 analogue) binds vitamin D receptors in skin cells to normalize their abnormally rapid growth and division, reducing plaque thickness and scaling. Together, these actions produce faster and more complete clearing of psoriatic plaques than either ingredient alone.

Planex Plus 20 gm may be used in adolescents aged 12 years and older for plaque psoriasis, with certain formulations specifically approved for this age group at a reduced maximum weekly quantity (typically 60 g/week) and treatment duration of up to 4 weeks, under close physician supervision. Safety and efficacy in children under 12 years have not been established, and Planex Plus 20 gm is generally not recommended for this younger population due to a higher risk of systemic corticosteroid absorption relative to body surface area.